ARTICLE | Clinical News
AGIX updates Phase II CART-1 data
November 12, 2001 8:00 AM UTC
AtheroGenics (AGIX) said its AGI-1067 met the primary endpoint of greater luminal diameters 6 months after angioplasty than placebo in a 305-patient Phase II Canadian Antioxidant Restenosis Trial (CAR...